PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
Abstract: lung cancer takes the second place in the general structure of incidence of malignant neoplasms in Russia. The diagnosis of a local or metastatic non small cells lung cancer (NSCLC) serves the indication to carrying out the 1st line chemotherapy. In case of progressing against or after the...
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Artigo |
| Lingua: | Russo |
| Pubblicazione: |
IRBIS LLC
2015-03-01
|
| Serie: | Фармакоэкономика |
| Soggetti: | |
| Accesso online: | https://www.pharmacoeconomics.ru/jour/article/view/35 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|